🔎 Trials Near Me

Beranda › Liposarcoma › Ohio

Uji klinis Liposarcoma di Ohio

6 studi untuk Liposarcoma mencari peserta di lokasi di Ohio.

Kota di Ohio

Teks studi resmi (Bahasa Inggris)

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • Miami Valley Hospital South, Centerville
  • dan 8 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06422806

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

  • Investigative Site, Canton
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06881992

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  • Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04031677

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

  • Gabrail Cancer Center, Canton
  • University Hospitals Cleveland Medical Center, Cleveland
  • Cleveland Clinic Taussig Cancer Institute, Cleveland
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06578624

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06239272

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

  • OSU James Hospital, Columbus
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT07377747

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.